Revolution Medicines, Inc. (NASDAQ:RVMD) Insider Sells $824,800.34 in Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) insider Stephen Michael Kelsey sold 16,666 shares of the stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $49.49, for a total value of $824,800.34. Following the transaction, the insider now owns 264,408 shares of the company’s stock, valued at approximately $13,085,551.92. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Revolution Medicines Stock Up 2.9 %

Shares of RVMD stock traded up $1.43 on Wednesday, reaching $50.42. The stock had a trading volume of 1,055,089 shares, compared to its average volume of 1,312,464. Revolution Medicines, Inc. has a 12 month low of $15.44 and a 12 month high of $51.00. The firm has a market capitalization of $8.42 billion, a price-to-earnings ratio of -13.46 and a beta of 1.43. The firm’s 50-day moving average is $44.35 and its two-hundred day moving average is $41.03.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.04). The firm had revenue of $1.00 million during the quarter, compared to the consensus estimate of $0.81 million. During the same period last year, the firm posted ($0.92) earnings per share. The firm’s revenue was down 73.8% on a year-over-year basis. On average, sell-side analysts forecast that Revolution Medicines, Inc. will post -3.35 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

RVMD has been the subject of several recent research reports. Jefferies Financial Group began coverage on Revolution Medicines in a research report on Monday, July 8th. They set a “buy” rating and a $63.00 price objective for the company. Barclays upped their price target on Revolution Medicines from $54.00 to $60.00 and gave the stock an “overweight” rating in a research report on Friday, September 27th. Wedbush reiterated an “outperform” rating and issued a $59.00 price objective on shares of Revolution Medicines in a report on Thursday, August 8th. Needham & Company LLC restated a “buy” rating and set a $61.00 target price on shares of Revolution Medicines in a report on Monday, October 7th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Revolution Medicines from $55.00 to $54.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $54.00.

Hedge Funds Weigh In On Revolution Medicines

Several institutional investors and hedge funds have recently modified their holdings of RVMD. GAMMA Investing LLC lifted its stake in shares of Revolution Medicines by 55.8% during the 3rd quarter. GAMMA Investing LLC now owns 620 shares of the company’s stock worth $28,000 after buying an additional 222 shares during the last quarter. Headlands Technologies LLC raised its holdings in Revolution Medicines by 140.9% in the 1st quarter. Headlands Technologies LLC now owns 1,513 shares of the company’s stock valued at $49,000 after acquiring an additional 885 shares during the period. Allspring Global Investments Holdings LLC acquired a new stake in Revolution Medicines during the first quarter worth approximately $104,000. EntryPoint Capital LLC bought a new stake in shares of Revolution Medicines during the first quarter worth approximately $107,000. Finally, Nisa Investment Advisors LLC grew its position in shares of Revolution Medicines by 10.5% in the second quarter. Nisa Investment Advisors LLC now owns 3,378 shares of the company’s stock valued at $131,000 after purchasing an additional 320 shares during the last quarter. 94.34% of the stock is currently owned by institutional investors and hedge funds.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.